J&J aims to build vaccines biz around Crucell

While Johnson & Johnson fights fires within its consumer drugs unit, it's looking to branch into the vaccines business. J&J says it's close to reaching a deal for Crucell, the Dutch vaccines maker, for €1.75 billion ($2.29 billion). The company already owns almost 18 percent of Crucell, but wants full control, so it can build a vaccines business around that core, the Wall Street Journal reports.

"Johnson & Johnson is a large pharmaceutical company that doesn't have a vaccine branch and vaccines are our claim to fame," Crucell CEO Ronald Brus tells the WSJ, "so for us, it's ... very encouraging[.]" J&J says it will keep Brus and other senior management and maintain its existing facilities, along with "generally" the same staffing.

The deal would give the already quite diversified J&J an even more diverse range of businesses. Getting into vaccines has been something of a trend in Big Pharma, as drugmakers look to spread into new markets to make up for generic competition for key drugs. In fact, some analysts think that the J&J talks could touch off a bidding war for Crucell, with Novartis and Pfizer as potential buyers. Others figure that's unlikely; indeed, J&J says due diligence is almost wrapped up and Brus predicts the deal will close by year's end.

- read the WSJ piece
- see the news from Reuters

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.